摘要
淀粉样变是一种全身性疾病,其临床表现和病理改变是淀粉样物质沉积于全身不同脏器所致.肾脏是淀粉样变最常受累的器官之一.淀粉样蛋白出现时,应及时进行分型,目的在于鉴定前体蛋白,并以此鉴定相应类型的淀粉样变.生物标记物的使用可以帮助鉴定淀粉样蛋白生成的前体,评估器官受累的存在和严重程度以及监测对治疗的反应.近年来研究发现,血清游离轻链（FLCs）可以成为免疫球蛋白轻链型（AL型）淀粉样变的生物标记物,靶向浆细胞抗原CD38和人源化2A4单克隆抗体NEOD001很有希望能成为AL型淀粉样变有效的治疗药物.
Amyloidosis is a systemic disease whose clinical manifestations and pathological changes are caused by the deposition of amyloid substances in different organs of the body.Kidney is one of the most frequently affected organs of amyloidosis.Amyloid protein should be genotyped in time, with the aim of identifying the precursor protein and identifying the corresponding type of amyloidosis.The use of biomarkers can help identify amyloid precursor, assess the presence and severity of organ involvement, and monitor the response to treatment. In recent years, the serum free light chain （FLCs） can be a biomarker of immunoglobulin light chain amyloidosis, targeting plasma cell antigen CD38（daratumumab） and humanized 2A4 monoclonal antibody NEOD001 is promising for immunoglobulin light chain amyloidosis to be an effective therapeutic agent.
出处
《中国医师进修杂志》
2017年第12期1139-1141,共3页
Chinese Journal of Postgraduates of Medicine
